Brenntag (BNR) CMD 2026 summary
Event summary combining transcript, slides, and related documents.
CMD 2026 summary
12 Nov, 2026Strategy and platform
Replacing two product-organized divisions with one customer-centered platform, combining broadline distribution with expertise-led verticals and full-portfolio access.
One account owner per customer, with coverage tailored to potential; verticals include Pharma, Nutrition, Water Treatment, Beauty & Care, Material Science and Oil & Gas.
Platform spans >160k customers, >10k supply partners, >20k products and >600 sites in >70 countries.
Since the 2020 divisional split, organic volumes lost market share; >10% of smaller customers were lost and 14% of customers buying Essentials and Specialties moved to one division.
Fragmented chemical and ingredient distribution market exceeds €700bn, with >30,000 distributors and a 2-3% share for the market leader.
Commercial growth
Shift from product push to market pull, with full-portfolio selling, customer win-back and retention, cross-selling, strategic partner relationships and pricing excellence.
Full-portfolio selling and customer initiatives are expected to contribute €1.7bn in sales, with a positive margin effect.
Regional vertical coverage identified 1,490 dormant prospects; common KPIs, scorecards and aligned incentives strengthen sales execution and pipeline discipline.
Harmonized pricing tools target a 1.2-1.7% opportunity; AI Bid Agent quotes 50% more RFQ line items with 80% less processing effort.
M&A and consolidation
M&A targets 1-2% annual operating EBITDA growth in a fragmented market, with disciplined focus on strategic fit, synergies and integration.
Medium-term cumulative bolt-on M&A spend is ~€1.5bn; acquisitions are targeted to become ROIC-accretive within 2-3 years.
Airedale, Chem Tech and Woojin Trading expand Water Treatment, Oil & Gas, Beauty & Care and regional platforms; Airedale adds >900 customers, ~50% new.
UK platform sales grew 2.1x and EBITDA 2.6x from 2015-2025.
Latest events from Brenntag
- Q3 EBITDA rose 14.5% FX-adjusted; FY26 guidance held toward the upper end.BNR
Q3 2026 (Pre recorded) - Q3 earnings grew and FY guidance held toward the upper end despite volatile costs.BNR
Q3 2026 - Strong Q2 2026 growth, margin expansion, and ESG leadership reinforce global market position.BNR
Investor presentation - Q2 EBITDA surged 41% and guidance was raised, despite persistent macroeconomic risks.BNR
Q2 2026 (Pre Recorded) - Q2 2026 delivered strong sales, profit growth, and raised guidance amid market volatility.BNR
Q2 2026 - Gross margin rose to 25.9% as sales fell 5.1% and EBITDA dropped 8.3% in Q1 2026.BNR
Q1 2026 - Sales and gross profit rose, but EBITA, EPS, and free cash flow declined in a tough Q3.BNR
Q3 2024 - Sales, EBITA, and cash flow fell in 2024, prompting lower guidance and major acquisitions.BNR
Q2 2024 - 2024 EBITDA fell 13% to €1.1bn; 2025 outlook expects moderate recovery amid uncertainty.BNR
Q4 2024